These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 23182840)

  • 1. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
    Becker S; Walter S; Witzke O; Kreuter A; Kribben A; Mitchell A
    Nephron Clin Pract; 2012; 121(1-2):c91-4. PubMed ID: 23182840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
    Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
    Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
    Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
    Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
    Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
    Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study.
    Amet S; Launay-Vacher V; Clément O; Frances C; Tricotel A; Stengel B; Gauvrit JY; Grenier N; Reinhardt G; Janus N; Choukroun G; Laville M; Deray G
    Invest Radiol; 2014 Feb; 49(2):109-15. PubMed ID: 24169070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
    Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
    AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006.
    Kendrick-Jones JC; Voss DM; De Zoysa JR
    Nephrology (Carlton); 2011 Feb; 16(2):243-8. PubMed ID: 21272139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure.
    Todd DJ; Kagan A; Chibnik LB; Kay J
    Arthritis Rheum; 2007 Oct; 56(10):3433-41. PubMed ID: 17907148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?
    Panesar M; Boateng F; Patel SS; Masood SF; Mahajan P; Patel N; Murray B
    Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine.
    Hope TA; Herfkens RJ; Denianke KS; LeBoit PE; Hung YY; Weil E
    Invest Radiol; 2009 Mar; 44(3):135-9. PubMed ID: 19151610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
    Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
    Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
    Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J
    Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadolinium and nephrogenic systemic fibrosis: have we overreacted?
    Penfield JG; Reilly RF
    Semin Dial; 2011; 24(5):480-6. PubMed ID: 21913988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.
    Tsushima Y; Kanal E; Thomsen HS
    Br J Radiol; 2010 Jul; 83(991):590-5. PubMed ID: 20413447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrogenic systemic fibrosis in advanced chronic kidney disease: a single hospital's experience in Taiwan.
    Chen W; Huang SL; Huang CS; Tsai MC; Lai HM; Lui CC; Eng HL; Chang HW; Lee CH; Chuang FR
    Eur J Dermatol; 2009; 19(1):44-9. PubMed ID: 19059824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study.
    Janus N; Launay-Vacher V; Karie S; Clement O; Ledneva E; Frances C; Choukroun G; Deray G
    Eur J Radiol; 2010 Feb; 73(2):357-9. PubMed ID: 19128909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrogenic systemic fibrosis: clinical picture and treatment.
    Marckmann P; Skov L
    Radiol Clin North Am; 2009 Sep; 47(5):833-40, vi. PubMed ID: 19744598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.